Hi mirri 11
As you mentioned that it was “distressing to see how much competition” there was at the Boswick Symposium, I’ve gone through the event schedule to identify which “competitive products” you might be referring to.
First there are the
animal-derived products
Integra’s flagship dermal matrix product,
Integra DRT is bovine and shark cartilage derived.
Matriderm, from German company, MedSkin Solutions Dr. Suwelack AG, is a collagen-elastin template based on bovine collagen.
Dermisphere, a newer product from Fesarius Therapeutics, consists of crosslinked bovine collagen microspheres embedded in bovine collagen hydrogel. Evidence to date seems confined to animal models.
Aroa ECM, made from sheep forestomach, should already be familiar to PNV investors.
Oasis matrix is a Smith and Nephew product that has been around for almost 20 years and is porcine derived.
Cytal matrix, a recent Integra acquisition, is derived from porcine urinary bladder.
Kerecis, a Norwegian fish skin derived product, has been discussed here previously on numerous occasions. It was recently acquired by Danish company, Coloplast. Product cost has been reported by surgeons at a New York hospital to be ~2.5 times that of BTM.
Cultured epidermal cell products (CES)
The
Recell product from Avita should already be familiar to PNV investors
Synthetic products
Aquacel is a double layer hydrofibre dressing with strengthening fibres. Hydrofiber is derived from 100% sodium carboxymethylcellulose. This product turns into a gel when in contact with the wounds’ exudate. It is a dressing indicated for use on moderately and highly exuding chronic and acute wounds. It’s not an implantable product. Aquacel can be left on for up to 7 days, depending on the level of exudate.
Microlyte Matrix is a product from Imbed Biosciences. It is an ultrathin polyelectrolyte matrix coated with a resorbable polymer which turns into a gel when in contact with the wounds’ exudate. The multi-layer sheet contains low amounts of metallic and ionic silver to provide antimicrobial benefit.
The presented case study at the Symposium describes treatment of a chronic venous leg ulcer. Preoperatively, the patient was treated with 3 applications of the antimicrobial matrix and 4-layer compression wraps over a week. The surgical technique consisted of meshed autograft with sprayed-on epidermal autografts and then immediate placement of the antimicrobial matrix followed by an outer dressing. The postoperative management included compression wraps and replacement of the matrix over areas of drainage with each dressing change. Sounds more complicated than Novosorb BTM to me…
SupraSDRM is a biodegradable synthetic dressing from German company, PolyMedics Innovations (PMI) which is PolyNovo’s distributor in Germany, Switzerland, Austria, Belgium, Netherlands, Luxembourg and Sweden.
SupraSDRM is fabricated from polylactic acid and received 510(k) clearance from the FDA in 2017. Therefore, when PolyNovo appointed PMI as a European distributor for BTM in 2019, it would have been well aware of this product. SupraSDRM was first discussed on this forum in 2019.
PMI describes SupraSDRM as a “dermal substitute” and Novosorb BTM as a “dermis substitute”. WoundSource says that SupraSDRM is indicated for superficial dermal wounds whereas Novosorb BTM is suitable for the treatment of full thickness wounds where the dermal structure has been lost.
If you are feeling distressed by the existence of SupraSDRM, consider this: SupraSDRM was approved in Europe in 2019, the same year in which PMI introduced Novosorb BTM into the German-speaking countries of Europe. By late last year, Novosorb BTM had become the market leading product in Germany (Swami Raote, PNV AGM 3/11/23).
https://www.woundsource.com/product...ynthetic-dressings/indicated-chronic-vascular
(20min delay)